Benzimidazole-carbamate anthelmintics: Perspective candidates for the anticancer drug development

被引:7
作者
Prasher, Parteek [1 ]
Sharma, Mousmee [2 ]
机构
[1] Univ Petr & Energy Studies, Dept Chem, Dehra Dun, Uttarakhand, India
[2] Uttaranchal Univ, Dept Chem, Dehra Dun, Uttarakhand, India
关键词
anthelmintics; anticancer; benzimidazole-carbamates; ALBENDAZOLE; TUBULIN;
D O I
10.1002/ddr.21933
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cellular oncogenesis involves a complex interplay between the several synchronized, interdependent pathways that collectively determine the pathogenesis and pathophysiology of cancer. Limited therapeutic success with the existing anticancer drugs drew huge interest in the design and development of new pharmacophores with improved clinical efficacy, however despite huge investments in anticancer RD; the average number of Food and Drug Administration-approved anticancer drugs declined since the 1990s. The contemporary anticancer medications possess high attrition rates, bear substantial costs, and experience low efficacy owing to the drug resistance expressed by the aggressive tumors. Mainly, the translation of novel candidate anticancer drugs into clinical practice, their commercialization, and transformation from the bench to bedside require a long timeframe of 10-15 years and capital worth millions of dollars. The repurposing strategy substantially accelerated the anticancer drug development regime as the approved drugs with tested safety and efficacy ensure a minimal risk of failure, and nominal R&D expenses as anticipated for the newly identified candidate drugs yet to enter the clinical trials. In addition, the repurposed drugs ensure a rapid clinical translation due to a validated clinical profile and their ability to target the identified hallmarks and hitherto unknown vulnerabilities of cancer. The flagship project "Repurposing Drugs in Oncology" (ReDO) identified 268 "hard repurposing" noncancer medications as candidate drugs with a promising anticancer profile (). However, the generic profile of 84% of repurposed drugs in ReDO data set discourages the commercial sponsors from funding the repurposing trials, especially the Phase III efficacy trials that require significant capital.
引用
收藏
页码:296 / 300
页数:5
相关论文
共 20 条
  • [1] Structure-based approaches for the design of benzimidazole-2-carbamate derivatives as tubulin polymerization inhibitors
    Aguayo-Ortiz, Rodrigo
    Cano-Gonzalez, Lucia
    Castillo, Rafael
    Hernandez-Campos, Alicia
    Dominguez, Laura
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2017, 90 (01) : 40 - 51
  • [2] A Comprehensive Account on Recent Progress in Pharmacological Activities of Benzimidazole Derivatives
    Brishty, Shejuti Rahman
    Hossain, Md. Jamal
    Khandaker, Mayeen Uddin
    Faruque, Mohammad Rashed Iqbal
    Osman, Hamid
    Rahman, S. M. Abdur
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [3] Albendazole as a promising molecule for tumor control
    Castro, L. S. E. P. W.
    Kviecinski, M. R.
    Ourique, F.
    Parisotto, E. B.
    Grinevicius, V. M. A. S.
    Correia, J. F. G.
    Wilhelm Filho, D.
    Pedrosa, R. C.
    [J]. REDOX BIOLOGY, 2016, 10 : 90 - 99
  • [4] Synthesis and anticancer activity of novel water soluble benzimidazole carbamates
    Cheong, Jae Eun
    Zaffagni, Michela
    Chung, Ivy
    Xu, Yingjie
    Wang, Yiqiang
    Jernigan, Finith E.
    Zetter, Bruce R.
    Sun, Lijun
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 144 : 372 - 385
  • [5] Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways
    Dogra, Nilambra
    Kumar, Ashok
    Mukhopadhyay, Tapas
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [6] The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer
    Florio, Rosalba
    Veschi, Serena
    di Giacomo, Viviana
    Pagotto, Sara
    Carradori, Simone
    Verginelli, Fabio
    Cirilli, Roberto
    Casulli, Adriano
    Grassadonia, Antonino
    Tinari, Nicola
    Cataldi, Amelia
    Amoroso, Rosa
    Cama, Alessandro
    De Lellis, Laura
    [J]. CANCERS, 2019, 11 (12)
  • [7] Gallia G.L., 2021, NEURO ONCOL ADV, V3
  • [8] Tautomerism in drugs with benzimidazole carbamate moiety: an electronic structure analysis
    Kasetti, Yoganjaneyulu
    Bharatam, Prasad V.
    [J]. THEORETICAL CHEMISTRY ACCOUNTS, 2012, 131 (03) : 1 - 12
  • [9] Computational repurposing of benzimidazole anthelmintic drugs as potential colchicine binding site inhibitors
    Khattab, Muhammad
    Al-Karmalawy, Ahmed A.
    [J]. FUTURE MEDICINAL CHEMISTRY, 2021, 13 (19) : 1623 - 1638
  • [10] G2/M arrest and mitotic slippage induced by fenbendazole in canine melanoma cells
    Kim, Sehoon
    Perera, Shashini Kanchanamala
    Choi, Seo-In
    Rebhun, Robert B.
    Seo, Kyoung-won
    [J]. VETERINARY MEDICINE AND SCIENCE, 2022, 8 (03) : 966 - 981